Predicted protein targets (top 15)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | HTR1D | P28221 | 1/20 | 0.39 |
| ▸ | CYP2C19 | P33261 | 4/20 | 0.37 |
| ▸ | CYP2C9 | P11712 | 3/20 | 0.36 |
| ▸ | HIF1A | Q16665 | 2/20 | 0.36 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.36 |
| ▸ | ESR1 | P03372 | 1/20 | 0.36 |
| ▸ | HSPA5 | P11021 | 2/20 | 0.35 |
| ▸ | PLAU | P00749 | 4/20 | 0.34 |
| ▸ | CYP2D6 | P10635 | 2/20 | 0.33 |
| ▸ | HSD17B10 | Q99714 | 1/20 | 0.33 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.32 |
| ▸ | CD69 | Q07108 | 1/20 | 0.32 |
| ▸ | TLR4 | O00206 | 2/20 | 0.32 |
| ▸ | CD14 | P08571 | 2/20 | 0.32 |
| ▸ | LY96 | Q9Y6Y9 | 2/20 | 0.32 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL10046770 | 0.93 | CYP2C19 (0.35) | HTR1DCYP2C19CYP2C9HIF1ASMN1; SMN2 | |
| SCHEMBL10046754 | 0.87 | HTR1D (0.31) | HTR1D | |
| SCHEMBL10046751 | 0.83 | HTR1D (0.34) | HTR1DCYP2C19CYP2C9HIF1ASMN1; SMN2 | |
| SCHEMBL13707222 | 0.82 | CYP2C19 (0.41) | CYP2C19CYP2C9HIF1ASMN1; SMN2ESR1 | |
| SCHEMBL10046776 | 0.82 | HTR1D (0.33) | HTR1DCYP2C19CYP2C9HIF1ASMN1; SMN2 | |
| SCHEMBL16501701 | 0.81 | CYP2C19 (0.36) | CYP2C19CYP2C9HIF1ASMN1; SMN2HSPA5 | |
| SCHEMBL13992487 | 0.81 | CYP1A2 (0.32) | HTR1DCYP2C19CYP2C9CYP2D6CYP1A2 | |
| SCHEMBL14213242 | 0.80 | CYP2C19 (0.33) | HTR1DCYP2C19CYP2C9CYP2D6CYP1A2 | |
| SCHEMBL10046743 | 0.79 | CYP2C19 (0.49) | HTR1DCYP2C19CYP2C9HIF1ASMN1; SMN2 | |
| SCHEMBL13992485 | 0.78 | HTR1D (0.41) | HTR1DCYP2D6CYP1A2CD69TLR4 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-8207228-B2 | Calixarene-based peptide conformation mimetics, methods of use, and methods of making | REGENTS OF THE UNIVERSITY OF MINNESOTA (US) | 2012-06-26 | — | — | US | disclosed |
| US-20080300164-A1 | Calixarene-Based Peptide Conformation Mimetics, Methods of Use, and Methods of Making | REGENTS OF THE UNIVERSITY OF MINNESOTA (US) | 2008-12-04 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20080300164-A1 | Calixarene-Based Peptide Conformation Mimetics, Methods of Use, and Methods of Making | CLSPN, BID, CALU | HTR1D 3528/4885CYP2C19 3478/4885CYP2C9 3820/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.